Increased alveolar soluble annexin v promotes lung inflammation and fibrosis

European Respiratory Journal

Volumn 46, Issue 5, 2015, Pages 1417-1429

  Buckley, Susan ^a   Shi, Wei ^a   Xu, Wei ^a   Frey, Mark R ^a   Moats, Rex ^a   Pardo, Annie ^b   Selman, Moises ^c   Warburton, David ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CXCL1 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROXYPROLINE; INTERLEUKIN 8; KERATINOCYTE DERIVED CHEMOKINE; LIPOCORTIN 5; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULOTROPIN; VIMENTIN; ERBB2 PROTEIN, HUMAN; ERBB2 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG FLUID; MALE; MITOGEN ACTIVATED PROTEIN KINASE SIGNALLING PATHWAY; NONHUMAN; NUCLEAR FACTOR KAPPA B SIGNALLING PATHWAY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA SIGNALLING PATHWAY; WNT SIGNALING PATHWAY; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; CELL CULTURE; CHEMISTRY; CYTOLOGY; EPITHELIUM CELL; GENETICS; LUNG ALVEOLUS; METABOLISM; MOUSE;

ANIMALS; ANNEXIN A5; BRONCHOALVEOLAR LAVAGE FLUID; CELLS, CULTURED; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PULMONARY ALVEOLI; RATS; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84946552488     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00002115     Document Type: Article

References (43)

1. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277-284.
2. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3: 364-372.
3. Collard HR. The age of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181: 771-772.
4. King T, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
5. Rescher U, Gerke V. Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 2004; 117: 2631-2639.
6. Vermes I, Haanen C, Steffens-Nakken H, et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39-51.
7. Bouter A, Gounou C, Bérat R, et al. Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair. Nat Commun 2011; 2: 270.
8. Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420-17423.
9. Cardó-Vila M, Arap W, Pasqualini R. αvβ5 integrin-dependent programmed cell death triggered by a peptide mimic of annexin V. Mol Cell 2003; 11: 1151-1162.
10. Kim KM, Kim DK, Park YM, et al. Annexin-I inhibits phospholipase A2 by specific interaction, not by substrate depletion. FEBS Lett 1994; 343: 251-255.
11. Wen Y, Edelman JL, Kang T, et al. Lipocortin V may function as a signaling protein for vascular endothelial growth factor receptor-2/Flk-1. Biochem Biophys Res Commun 1999; 258: 713-721.
12. Sohma H, Onkawa H, Akino T, et al. Binding of annexins to lung lamellar bodies and the PMA-stimulated secretion of annexin V from alveolar type II cells. J Biochem 2001; 130: 449-455.
13. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007; 2: e482.
14. Gonzalez RF, Dobbs LG. Isolation and culture of alveolar epithelial Type I and Type II cells from rat lungs. Methods Mol Biol 2013; 945: 145-159.
15. Wikenheiser KA, Vorbroker DK, Rice WR, et al. Production of immortalized distal respiratory epithelial cell lines from surfactant protein C/simian virus 40 large tumor antigen transgenic mice. Proc Natl Acad Sci USA 1993; 90: 11029-11033.
16. Ewing MM, de Vries MR, Nordzell M, et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol 2011; 31: 95-101.
17. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60: 532-538.
18. McGrath-Morrow S, Rangasamy T, Cho C, et al. Impaired lung homeostasis in neonatal mice exposed to cigarette smoke. Am J Respir Cell Mol Biol 2008; 38: 393-400.
19. Matsuba K, Thurlbeck WM. The number and dimensions of small airways in emphysematous lungs. Am J Pathol 1972; 67: 265-275.
20. Malyala P, Singh M. Endotoxin limits in formulations for preclinical research. J Pharm Sci 2008; 97: 2041-2044.
21. 1 in fetal monkey lung results in prenatal pulmonary fibrosis. Eur Respir J 2010; 36: 907-914.
22. Shevchenko A, Tomas H, Havlis J, et al. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 2006; 1: 2856-2860.
23. Berndsen CE, Tsubota T, Lindner SE, et al. Molecular functions of the histone acetyltransferase chaperone complex Rtt109-Vps75. Nat Struct Mol Biol 2008; 15: 948-956.
24. Sadygov RG, Cociorva D, Yates JR III. Large-scale database searching using tandem mass spectra: looking up the answer in the back of the book. Nat Methods 2004; 1: 195-202.
25. Bui K, Buckley S, Wu F, et al. Induction of A-and D-type cyclins and cdc2 kinase activity during recovery from short-term hyperoxic lung injury. Am J Physiol Lung Cell Mol Physiol 1995; 268: L625-L635.
26. Hol J, Wilhelmsen L, Haraldsen G. The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies. J Leukoc Biol 2010; 87: 501-508.
27. DePianto DJ, Chandriani S, Abbas AR, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 2015; 70: 48-56.
28. Hara A, Sakamoto N, Ishimatsu Y, et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med 2012; 106: 571-580.
29. Hamada N, Maeyama T, Kawaguchi T, et al. The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39: 440-447.
30. Bitto A, Barone M, David A, et al. High mobility group box-1 expression correlates with poor outcome in lung injury patients. Pharmacol Res 2010; 61: 116-120.
31. Korfei M, Schmitt S, Ruppert C, et al. Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs. J Proteome Res 2011; 10: 2185-2205.
32. Huang RY, Wong MK, Tan TZ, et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis 2013; 4: e915.
33. Eming SA, Koch M, Krieger A, et al. Differential proteomic analysis distinguishes tissue repair biomarker signatures in wound exudates obtained from normal healing and chronic wounds. J Proteome Res 2010; 9: 4758-4766.
34. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173: 188-198.
35. Hinata N, Takemura T, Ikushima S, et al. Phenotype of regenerative epithelium in idiopathic interstitial pneumonias. J Med Dent Sci 2003; 50: 213-224.
36. Kim TH, Lee YH, Kim KH, et al. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med 2010; 182: 633-642.
37. Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res 2012; 72: 5261-5272.
38. Kono M, Nakamura Y, Suda T, et al. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta 2011; 412: 2211-2215.
39. Kotani I, Sato A, Hayakawa H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.
40. Garcia O, Carraro G, Turcatel G, et al. Amniotic fluid stem cells inhibit the progression of bleomycin-induced pulmonary fibrosis via CCL2 modulation in bronchoalveolar lavage. PLoS One 2013; 8: e71679.
41. Elliott MR, Ravichandran KS. Clearance of apoptotic cells: implications in health and disease. J Cell Biol 2010; 189: 1059-1070.
42. Königshoff M, Balsara N, Pfaff EM, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008; 3: e2142.
43. Kim JS, Choi IG, Lee BC, et al. Neuregulin induces CTGF expression in hypertrophic scarring fibroblasts. Mol Cell Biochem 2012; 365: 181-189.